Lunai Bioworks Inc.
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $537,428 | $2.7M | $4.2M | $8.4M | $15.7M |
| Operating expenses | $189.0M | $81.6M | $38.6M | $116.1M | $23.4M |
| Operating income | -$189.0M | -$81.6M | -$38.6M | -$116.1M | -$23.4M |
| Interest expense | $725,684 | $1.0M | $580,344 | $372,844 | $379,608 |
| Pretax income | — | — | -$39.7M | -$113.4M | -$26.8M |
| Income tax expense | $1,474 | $0 | $0 | $34 | -$125,276 |
| Net income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.7M |
| Balance Sheet | |||||
| Cash and equivalents | $92,700 | $220,467 | $1.9M | $9.2M | $20.7M |
| Current assets | $1.0M | $2.0M | $2.6M | $9.6M | $20.9M |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M |
| Current liabilities | $29.2M | $30.3M | $11.0M | $6.5M | $1.9M |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M |
| Stockholders' equity | -$21.3M | $132.0M | $46.5M | $72.6M | $174.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.9M | -$11.0M | -$11.8M | -$15.7M | -$20.6M |
| Depreciation and amortization | $129,095 | $121,859 | $113,496 | $123,590 | $123,535 |
| Stock-based compensation | $3.3M | $4.7M | $3.5M | $5.2M | $1.3M |
| Capital expenditure | — | $70,430 | $29,774 | $5,156 | $48,892 |
| Free cash flow | — | -$11.0M | -$11.8M | -$15.7M | -$20.7M |
| Impairments | $0 | $0 | $0 | $93.3M | — |
Shares outstanding 36.3M
Annual filing data through FY ended June 30, 2025; float as of July 14, 2026.